Tests teclistamab with daratumumab in people with AL amyloidosis
Tests whether teclistamab with daratumumab helps adults newly diagnosed with AL amyloidosis.
Plain-language title generated from the registry record
Registry title: Teclistamab-Daratumumab in AL Amyloidosis
Key facts
- Where
- Boston, Milwaukee, and New York, United StatesSee the 3 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07110844, who can take part
Where in United States
- Boston Medical CenterBoston, United StatesNot yet recruiting
- Medical College of WisconsinMilwaukee, United StatesTaking people
- Columbia University Irving Medical CenterNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rajshekhar Chakraborty, MD
- Trial code
- NCT07110844
- Record updated
- 13 July 2026
- Original description
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.Read full original descriptionShow less
A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis
The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.
The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Inclusion: Age >18 years and able to sign Informed Consent Form (ICF). If the individual being considered for participation in this study is unable to provide informed consent due to medical, cognitive, or other conditions, a legally authorized representative (LAR) may consent on their behalf; Ability to comply with the study protocol, in the investigator's judgment; Confirmed histopathological diagnosis of systemic AL amyloidosis by mass spectrometry or immunohistochemistry (IHC) or Immunofluorescence (IF) on a tissue biopsy that is positive for Congo Red; Patient must not have received any prior plasma cell clone-directed therapy; Measurable hematologic disease, defined as one of the following:; Difference between involved and uninvolved serum free light chain (dFLC) ≥50 mg/L and/or 5 mg/dL; Serum M-protein ≥0.5 g/dL on protein electrophoresis; Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2; One or more organs involved by AL amyloidosis as per consensus guidelines; Pre-treatment clinical laboratory values meeting the following criteria during the screening phase:; Absolute neutrophil count ≥0.75 × 10\^9/L; Hemoglobin level ≥8.0 g/dL; red blood cell transfusion allowed until 7 days before C1D0; Platelet count ≥50 × 10\^9/L; Platelet transfusions are acceptable without restriction during the Screening period; Alanine aminotransferase level (ALT) ≤2.5 times the Upper Limit of Normal (ULN); Aspartate aminotransferase (AST) ≤2.5 times the ULN; Total bilirubin level ≤1.5 × ULN except for subjects with Gilbert syndrome, in which case direct bilirubin ≤2 × ULN; Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73 m\^2, measured by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs; For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.
Exclusion: Prior therapy for AL amyloidosis or multiple myeloma with the exception of 160 mg dexamethasone (or equivalent corticosteroid) maximum exposure prior to C1D0; Patients on renal replacement therapy; Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted, as per investigators' discretion; Patients who are receiving any other investigational agent concurrently; Evidence of significant cardiovascular conditions as specified below:; NT-Pro BNP > 8500 pg/mL, and/or; NYHA Class IIIb or IV functional class; Evidence of other clinically significant uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal); Patients with HIV who are not on HAART or those with active hepatitis A, B, or C infection; Known hypersensitivity to any of the agents; Patients meeting criteria for symptomatic multiple myeloma by any one of the following: (a) Lytic lesions on imaging (Skeletal survey, whole body CT or MRI, or PET/CT) (b) Plasmacytoma, (c) Hypercalcemia without any alternate etiology, (d) Bone marrow plasma cell infiltrate of greater than 60%; Patients with involved/uninvolved serum FLC ratio>100 as the sole myeloma-defining event will be allowed; History of other malignancy that could affect compliance with the protocol or interpretation of results; Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, breast cancer, or Hodgkin's Lymphoma are generally eligible. Patients with a malignancy that has been treated, but not with curative intent, will be excluded, unless the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment.